Andexanet alpha versus four-factor prothrombin complex concentrate in direct oral anticoagulants (DOACs) anticoagulation reversal: an updated systematic review and meta-analysis
Pooled result · All-cause short-term mortality, RCTs and PSMsResult — go to the resultRelative risk 0.71 95% CI 0.37–1.34Authors' conclusion
Considering a large group of both retrospective and controlled studies, Andexanet alpha did not show a statistically significant advantage over 4F-PCC in terms of mortality. In the analysis of the controlled studies alone, Andexanet alpha is associated with an increased risk of thromboembolic events.
Study context
- Population
- Patients requiring reversal of DOAC anticoagulation22 studies
- Comparison
- Andexanet alpha vs 4F-PCC for DOAC anticoagulation reversal
- Outcome
- Short-term all-cause mortality
Methodological detailsupdated
- Updated
Pooled result
All-cause short-term mortality, RCTs and PSMs
Relative risk
0.71
95% CI 0.37–1.34
Andexanet alpha vs 4F-PCC
RR 0.71 (95% CI 0.37–1.34)
As reported in the abstract
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Thromboembolic events, RCTs and PSMsAndexanet alpha vs 4F-PCC · common effects model | 1.74 (1.09–2.77) | |
| Thromboembolic events, RCTs and PSMsAndexanet alpha vs 4F-PCC · random effects model | 1.71 (1.01–2.89) | |
| 0.20.5125Relative risk (log scale) |
- Thromboembolic events, RCTs and PSMs: I2 = 0%
Original publication
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis. Crit Care. Published 5 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →